Potential of Fasting C-peptide to Glucose Ratio and Triglyceride Glucose Index As Markers for β-Cell Dysfunction and Insulin Resistance in Patients With Type 2 Diabetes on Insulin Therapy

Overview

Journal Cureus

Specialty Biomedical Engineering

Date 2024 Sep 10

PMID 39252700

Authors

Breshan S Essa

Mohammed Q Meena

Affiliations

Soon will be listed here.

Abstract

Background: Pathogenesis of type 2 diabetes mellitus (T2DM) is combined from initial insulin resistance (IR) and subsequent β-cell dysfunction. Insulin therapy can replace β-cell function in advanced stages. However excessive insulin therapy increases IR and may expose the patients to risk of cardiovascular disease. We aim to assess β-cell function and IR in patients with type 2 diabetes on insulin therapy by fasting C-peptide to glucose ratio (FCPGR), and triglyceride glucose (TyG) index respectively to support treatment plans.

Method: A cross-sectional study was conducted at the Galiawa Diabetes and Endocrinology Teaching Center in Erbil City, Iraq, from June 2023 to January 2024. A convenient sample of 100 patients with T2DM on insulin-based therapy were included after obtaining informed written consent and excluding conditions such as acute illness, uncertain type of diabetes, etc. Each patient was evaluated for anthropometric parameters and current treatment details. Biochemical tests were then carried out to calculate metabolic syndrome (MetS) index score, FCPGR, and TyG index. Finally, patients were divided into four subgroups according to their FCPGR and TyG index and the data were analyzed statistically.

Result: The data showed those patients with sufficient β-cell function were 60 (60%), and patients with high TyG index were 95 (95%). There was a significant negative correlation between FCPGR and hemoglobin A1c (HbA1c) (p-value=0.001), while there was a positive correlation between TyG index and HbA1C (p-value=0.001). None of these markers were correlated with BMI (p-value=0.297, and 0.976), duration of T2DM (p-value=0.258, and 0.458), and dose of insulin therapy (p-value=0.901, and 0.477). Patients with sufficient β-cell function and high TyG index had the lowest HbA1C.

Conclusion: The study provides valuable insights into the utility of FCPGR and TyG index as biomarkers for β-cell function and insulin resistance in T2DM patients on insulin therapy. The significant correlation with HbA1C underscores their potential in clinical practice. However, the lack of correlation with BMI, disease duration, and insulin dose suggests that further investigation is needed to fully understand these biomarkers' implications across diverse patient profiles.

References

Saisho Y . Postprandial C-Peptide to Glucose Ratio as a Marker of β Cell Function: Implication for the Management of Type 2 Diabetes. Int J Mol Sci. 2016; 17(5). PMC: 4881566. DOI: 10.3390/ijms17050744. View

Filippatos T, Tsimihodimos V, Pappa E, Elisaf M . Pathophysiology of Diabetic Dyslipidaemia. Curr Vasc Pharmacol. 2017; 15(6):566-575. DOI: 10.2174/1570161115666170201105425. View

Leahy J . Pathogenesis of type 2 diabetes mellitus. Arch Med Res. 2005; 36(3):197-209. DOI: 10.1016/j.arcmed.2005.01.003. View

Funakoshi S, Fujimoto S, Hamasaki A, Fujiwara H, Fujita Y, Ikeda K . Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes. J Diabetes Investig. 2014; 2(4):297-303. PMC: 4014971. DOI: 10.1111/j.2040-1124.2010.00096.x. View

Kautzky-Willer A, Leutner M, Harreiter J . Sex differences in type 2 diabetes. Diabetologia. 2023; 66(6):986-1002. PMC: 10163139. DOI: 10.1007/s00125-023-05891-x. View

Mansour A, Al-Jazairi M . Cut-off values for anthropometric variables that confer increased risk of type 2 diabetes mellitus and hypertension in Iraq. Arch Med Res. 2007; 38(2):253-8. DOI: 10.1016/j.arcmed.2006.09.014. View

Iwao T, Sakai K, Sata M . Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes. J Diabetes Complications. 2012; 27(1):87-91. DOI: 10.1016/j.jdiacomp.2012.07.001. View

Simental-Mendia L, Guerrero-Romero F . The correct formula for the triglycerides and glucose index. Eur J Pediatr. 2020; 179(7):1171. DOI: 10.1007/s00431-020-03644-1. View

Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D . Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008; 371(9626):1753-60. DOI: 10.1016/S0140-6736(08)60762-X. View

10.

Selvi N, Nandhini S, Sakthivadivel V, Lokesh S, Srinivasan A, Sumathi S . Association of Triglyceride-Glucose Index (TyG index) with HbA1c and Insulin Resistance in Type 2 Diabetes Mellitus. Maedica (Bucur). 2021; 16(3):375-381. PMC: 8643546. DOI: 10.26574/maedica.2021.16.3.375. View

11.

Willey K, Fiatarone Singh M . Battling insulin resistance in elderly obese people with type 2 diabetes: bring on the heavy weights. Diabetes Care. 2003; 26(5):1580-8. DOI: 10.2337/diacare.26.5.1580. View

12.

Guerrero-Romero F, Simental-Mendia L, Gonzalez-Ortiz M, Martinez-Abundis E, Ramos-Zavala M, Hernandez-Gonzalez S . The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010; 95(7):3347-51. DOI: 10.1210/jc.2010-0288. View

13.

Kaga H, Tamura Y, Takeno K, Kakehi S, Someya Y, Funayama T . Higher C-Peptide Level During Glucose Clamp Is Associated With Muscle Insulin Resistance in Nonobese Japanese Men. J Endocr Soc. 2019; 3(10):1847-1857. PMC: 6753586. DOI: 10.1210/js.2019-00167. View

14.

Lee J, Kim M, Jang J, Oh C . Assessment HOMA as a predictor for new onset diabetes mellitus and diabetic complications in non-diabetic adults: a KoGES prospective cohort study. Clin Diabetes Endocrinol. 2023; 9(1):7. PMC: 10652621. DOI: 10.1186/s40842-023-00156-3. View

15.

Goodall G, Sarpong E, Hayes C, Valentine W . The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study. BMC Endocr Disord. 2009; 9:19. PMC: 2761913. DOI: 10.1186/1472-6823-9-19. View

16.

Vidal-Ostos F, Ramos-Lopez O, Blaak E, Astrup A, Martinez J . The triglyceride-glucose index as an adiposity marker and a predictor of fat loss induced by a low-calorie diet. Eur J Clin Invest. 2021; 52(1):e13674. DOI: 10.1111/eci.13674. View

17.

Son D, Lee H, Lee Y, Lee J, Han J . Comparison of triglyceride-glucose index and HOMA-IR for predicting prevalence and incidence of metabolic syndrome. Nutr Metab Cardiovasc Dis. 2022; 32(3):596-604. DOI: 10.1016/j.numecd.2021.11.017. View

18.

Alam F, Islam M, Mohamed M, Ahmad I, Kamal M, Donnelly R . Efficacy and Safety of Pioglitazone Monotherapy in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Sci Rep. 2019; 9(1):5389. PMC: 6441028. DOI: 10.1038/s41598-019-41854-2. View

19.

Mendez C, Walker R, Eiler C, Mishriky B, Egede L . Insulin therapy in patients with type 2 diabetes and high insulin resistance is associated with increased risk of complications and mortality. Postgrad Med. 2019; 131(6):376-382. PMC: 7052790. DOI: 10.1080/00325481.2019.1643635. View

20.

Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S . The metabolically obese, normal-weight individual revisited. Diabetes. 1998; 47(5):699-713. DOI: 10.2337/diabetes.47.5.699. View